疏肝降脂颗粒治疗非酒精性脂肪性肝炎临床观察
|
摘要
目的:观察疏肝降脂颗粒治疗非酒精性脂肪性肝炎(NASH)的临床疗效。方法:将200例明确诊断为NASH患者,随机分成两组,每组100例,治疗组患者口服疏肝降脂颗粒25g/次,3次/d,对照组患者口服当飞利肝宁胶囊1.0g/次,3次/d,两组患者疗程均为3个月。观察两组患者治疗前后血清天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、碱性磷酸酶(ALP)、γ-谷氨酰转移酶(γ-GT);血脂总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL);肝脏与脾脏的CT值比值等变化和临床疗效。结果:与治疗前相比较,治疗组患者肝功能、血脂指标均有显著下降,且在改善肝功能、血脂方面均优于对照组,差异有显著性意义(P<0.01)。肝/脾CT比值均有所升高,治疗组升高的较对照组明显,差异有统计学意义(P<0.05)。治疗组总有效为92%,对照组总有效率为83%,两组比较差异有显著性意义(P=0.02<0.05)。结论:疏肝降脂颗粒治疗NASH有良好的效果。
Objective: To observe the clinical curative effect of Shugan Jiangzhi Granules on Non-Alcoholic Fatty Liver Disease( NAFLD). Methods: Two hundred patients with definite diagnosis of NAFLD were randomly divided into two groups( 100 cases in each group). The treatment group was given Shugan Jiangzhi Granules 25 g/time,3 times/d orally. The control group was treated with Feili Ganning Capsules 1. 0 g/time,3 times/d orally. The two groups were treated for 3 months,observed the patients before and after treatment with liver function tests of serum enzyme aspartate transaminase( AST),alanine aminotransferase( ALT),alkaline phosphatase( ALP),γ-glutamyl transferase( r-GT),total cholesterol( TC),triglyceride( TG),high density lipoprotein cholesterol( HDL),CT value of liver and spleen and the changing of clinical efficacy. Results: Compared with those before treatment,the indexes of the liver function and blood lipid of the treatment group were significantly decreased,and the improvement of liver function and blood lipid were better than the control group( P< 0. 01). Liver/spleen CT ratio increased,the treatment group increased significantly more than the control group,the difference was statistically significant( P < 0. 05). The total effective rate was 92% in the treatment group and 80% in the control group. The difference between the two groups was significant( P = 0. 02 < 0. 05). Conclusion: Shugan Jiangzhi Granules was particularly effective in the treatment of Non-Alcoholic Fatty Liver Disease.
Objective: To observe the clinical curative effect of Shugan Jiangzhi Granules on Non-Alcoholic Fatty Liver Disease( NAFLD). Methods: Two hundred patients with definite diagnosis of NAFLD were randomly divided into two groups( 100 cases in each group). The treatment group was given Shugan Jiangzhi Granules 25 g/time,3 times/d orally. The control group was treated with Feili Ganning Capsules 1. 0 g/time,3 times/d orally. The two groups were treated for 3 months,observed the patients before and after treatment with liver function tests of serum enzyme aspartate transaminase( AST),alanine aminotransferase( ALT),alkaline phosphatase( ALP),γ-glutamyl transferase( r-GT),total cholesterol( TC),triglyceride( TG),high density lipoprotein cholesterol( HDL),CT value of liver and spleen and the changing of clinical efficacy. Results: Compared with those before treatment,the indexes of the liver function and blood lipid of the treatment group were significantly decreased,and the improvement of liver function and blood lipid were better than the control group( P< 0. 01). Liver/spleen CT ratio increased,the treatment group increased significantly more than the control group,the difference was statistically significant( P < 0. 05). The total effective rate was 92% in the treatment group and 80% in the control group. The difference between the two groups was significant( P = 0. 02 < 0. 05). Conclusion: Shugan Jiangzhi Granules was particularly effective in the treatment of Non-Alcoholic Fatty Liver Disease.
引文
[1]葛均波,徐永健.内科学[M].北京:人民卫生出版社,2014:408.
[2]Wong VW,Chu WC,Wong GL,et al.Prevalence of nonalcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese:a population study using proton-magnetic resonance spectroscopy and transient elast ography[J].Gut,2012,61(3):409-415.
[3]Hassan K,Bhalla V,Ragal MEE,et,al.Nonalcoholic fatty liver disease:A comprehensive review of a growing epidemic[J].World Journal of GAST roenterology,2014,20(34):12082-12101.
[4]中华医学会肝脏病学分会脂肪肝和非酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2010,18(3):163~166.
[5]中国中西医结合学会消化系统疾病专业委员会.非酒精性脂肪性肝病的中西医结合诊疗共识意见[J].中国中西医结合杂志,2011,31(2):156.
[6]王世荣.分析柴胡皂苷对肝脏的药理毒理作用[J].世界最新医学信息文摘,2015,15(2):55-57.
[7]阳柳平.研究白术的化学成分及药理作用概况[J].中国医药指南,2012,21(10):607-609.
[8]冯岩,胡建平,周洪,等.基于中医传承辅助系统治疗脂肪肝方剂用药规律分析[J].中国实验方剂学杂志,2012,18(11):5-8.
[9]胡波,范红伟,马广骏.丹参有效单体IH764-3药理作用研究及其临床应用前景述评[J].白求恩医学杂志,2016,14(2):233-235.
[10]许耀宗.决明子的现代药理药性与临床新用研究[J].北方药学,2016,13(4):136-137.
[2]Wong VW,Chu WC,Wong GL,et al.Prevalence of nonalcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese:a population study using proton-magnetic resonance spectroscopy and transient elast ography[J].Gut,2012,61(3):409-415.
[3]Hassan K,Bhalla V,Ragal MEE,et,al.Nonalcoholic fatty liver disease:A comprehensive review of a growing epidemic[J].World Journal of GAST roenterology,2014,20(34):12082-12101.
[4]中华医学会肝脏病学分会脂肪肝和非酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2010,18(3):163~166.
[5]中国中西医结合学会消化系统疾病专业委员会.非酒精性脂肪性肝病的中西医结合诊疗共识意见[J].中国中西医结合杂志,2011,31(2):156.
[6]王世荣.分析柴胡皂苷对肝脏的药理毒理作用[J].世界最新医学信息文摘,2015,15(2):55-57.
[7]阳柳平.研究白术的化学成分及药理作用概况[J].中国医药指南,2012,21(10):607-609.
[8]冯岩,胡建平,周洪,等.基于中医传承辅助系统治疗脂肪肝方剂用药规律分析[J].中国实验方剂学杂志,2012,18(11):5-8.
[9]胡波,范红伟,马广骏.丹参有效单体IH764-3药理作用研究及其临床应用前景述评[J].白求恩医学杂志,2016,14(2):233-235.
[10]许耀宗.决明子的现代药理药性与临床新用研究[J].北方药学,2016,13(4):136-137.